在2型糖尿病中,牙周组织对血糖控制的敏感性
Moe Inoue1,2, Akito Sakanaka1, Naoto Katakami3
1Department of Preventive Dentistry, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan.
Diabetes, obesity & metabolism
|August 14, 2024
概括
密集的血糖控制显著改善了2型糖尿病患者的牙周健康状况. 牙周愈合是多样化的,受个人系统性疾病的影响,突出显示了整体健康管理的重要性.
科学领域:
- 内分泌学 在内分泌学.
- 牙周病学 牙周病学
- 内部医学 内部医学
背景情况:
- 糖尿病与牙周病的风险增加有关.
- 糖尿病的有效管理可能会影响全身和口腔健康结果.
研究的目的:
- 评估密集血糖控制对牙周组织的直接影响.
- 在糖尿病患者中确定与牙周炎症相关的全身和口腔指标.
主要方法:
- 29名2型糖尿病患者接受了为期2周的密集血糖控制方案.
- 在干预之前和之后测量了全身和口腔疾病指标.
- 使用牙周炎症表面积 (PISA) 来评估牙周炎症.
主要成果:
- 密集的血糖控制导致糖性专辑蛋白和PISA显著减少.
- 牙周愈合 (每颗牙的PISA变化) 显示出双模分布,将患者分为改善和不改善的组.
- 特定的代谢和心血管标志物与牙周改善相关,并且在患者组之间有所不同.
结论:
- 密集的血糖控制可以有效地改善2型糖尿病患者的牙周炎,而无需特殊的牙周治疗.
- 牙周改善的程度取决于患者的整体系统状况.
- 进一步的研究可能会阐明基于全身健康状况的个性化治疗策略.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Carbohydrate Metabolism
10.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.9K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Pathophysiology of Diabetes
910
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
910
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167


